Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...

VIJAYAWADA: Sickle cell anaemia and thalassemia remain major health concerns in the State, particularly among tribal ...

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

After moving from Sierra Leone to London, guest columnist Richard Bayliss received a proper diagnosis and care plan for his ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Clinical trials for exa-cel have shown promising results that it has been authorised by the FDA and MHRA for use in beta thalassemia and sickle cell disease. These successes make CRISPR technology, as ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

A gene-editing therapy for sickle cell ... living with sickle cell has access to the care, treatments, and support they ...

Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...